Antibody drug conjugates (ADCs) are a new class of anti-tumor drugs in which linkers in the structure link cytotoxic drugs to monoclonal antibodies and release cytotoxic drugs to tumors. Disitamab vedotin (RC48) is a new antibody-drug conjugate independently developed in China. It targets the HER2 protein on the surface of tumors, it has both antibody targeting and small molecule drug killing, and can accurately recognize and kill tumor cells. Compared with traditional HER2-targeted drugs, disitamab vedotin has a wider therapeutic window and less toxicity to normal tissues. Currently, disitamab vedotin for injection has been approved by the National Medical Products Administration (NMPA) for use in patients with HER2 overexpression (HER2 immunohistochemical results of 2+ or 3+) who have locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) and have received at least two types of systemic chemotherapy. Additionally, it is indicated for patients with locally advanced or metastatic urothelial carcinoma who have previously undergone platinum-containing chemotherapy and exhibit HER2 overexpression, specifically 2+ or 3+ immunohistochemical results. In this paper, we will review the structural characteristics, mechanism of action and clinical trials of disitamab vedotin and look forward to the clinical application prospects of this drug.